Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Diluted Average) (2025)

Historic Shares Outstanding (Diluted Average) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $129.0 million.

  • Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) fell 373.13% to $129.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year decrease of 373.13%. This contributed to the annual value of $133.0 million for FY2024, which is 3499999990000.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Shares Outstanding (Diluted Average) of $129.0 million as of Q3 2025, which was down 373.13% from $126.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $139.0 million in Q4 2022 and a low of $0.31 during Q1 2023
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $62.5 million (2023), whereas its average is $65.9 million.
  • Data for Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increase of 3676470578235.29% (in 2025) and a maximum YoY decrease of 373.13% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $139.0 million in 2022, then dropped by 1.44% to $137.0 million in 2023, then decreased by 2.92% to $133.0 million in 2024, then fell by 3.01% to $129.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $129.0 million for Q3 2025, versus $126.0 million for Q2 2025 and $125.0 million for Q1 2025.